XMT-1660: A PHASE 1B TRIAL OF A B7-H4 TARGETING ANTIBODY DRUG CONJUGATE (ADC) IN ENDOMETRIAL, OVARIAN, AND BREAST CANCERS

被引：0

作者：

Hamilton, Erika ^{[1
]}

Chaudhry, Arvind ^{[2
]}

Spira, Alex ^{[3
]}

Adams, Sylvia ^{[4
]}

Abuhadra, Nour ^{[5
]}

Giordano, Antonio ^{[6
]}

Parajuli, Ritesh ^{[7
]}

Han, Hyo ^{[8
]}

Weise, Amy ^{[9
]}

Marchesani, Aubri ^{[6
,10
]}

Josephs, Kate ^{[11
]}

Im, Ellie ^{[11
]}

Shin, Chu Ri ^{[11
]}

Kalinsky, Kevin ^{[12
]}

机构：

[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[2] Spokane Valley Canc Ctr, Med Oncol, Spokane, WA USA

[3] Virginia Canc Specialists, Med Oncol, Fairfax, VA USA

[4] NYU Langone, Perlmutter Canc Ctr, Med Oncol, New York, NY USA

[5] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA

[6] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[7] Univ Calif, Irvine Med Ctr, Med Oncol, Orange, CA USA

[8] H Lee Moffitt Canc Ctr & Res Inst, Breast Oncol, Tampa, FL USA

[9] Henry Ford Hlth Syst, Med Oncol, Novi, MI USA

[10] Mersana Therapeut, Clin Operat, Cambridge, MA USA

[11] Mersana Therapeut, Clin Dev, Cambridge, MA USA

[12] Winship Canc Inst, Breast Oncol, Atlanta, GA USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷

关键词：

D O I：

10.1136/ijgc-2022-igcs.521

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TP012/#142

引用

页码：A228 / A229

页数：2

共 50 条

[41] Development and functional characterization of NC762, a novel therapeutic antibody targeting B7-H4, for the treatment of malignancies.
Archer, Kristina
Ceradoy, Justine
Coupet, Tiffany
Bosiacki, Jason
Song, Chang
Weiss, Ido
Niu, Sue
Obot, Tete
Xu, Jinglin
O'Neill, Tom
Ferrell, Alison
Abukharma, Hasan
Cusumano, Zac
Flies, Dallas
Langermann, Sol
Liu, Linda N.
CANCER RESEARCH, 2021, 81 (13)
[42] Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas
Niu, Na
Shen, Weiwei
Zhong, Yanping
Bast, Robert C., Jr.
Jazaeri, Amir
Sood, Anil K.
Liu, Jinsong
HUMAN PATHOLOGY, 2021, 113 : 20 - 27
[43] Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Jang, Sekwon
Powderly, John D.
Spira, Alexander I.
Bakkacha, Ouiam
Loo, Deryk
Bohac, Gerry C.
Sharma, Manish
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[44] B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer
Ling Wang
Chao Yang
Xin-bo Liu
Li Wang
Fu-biao Kang
Cancer Cell International, 18
[45] B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer
Wang, Ling
Yang, Chao
Liu, Xin-bo
Wang, Li
Kang, Fu-biao
CANCER CELL INTERNATIONAL, 2018, 18
[46] Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.
Hamilton, Erika Paige
Barve, Minal A.
Bardia, Aditya
Beeram, Muralidhar
Bendell, Johanna C.
Mosher, Rebecca
Hailman, Eric
Bergstrom, Donald Alan
Burris, Howard A.
Soliman, Hatem Hussein
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[47] A phase 1 dose escalation/expansion study of GSK5764227 (GSK'227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors, including gastrointestinal (GI) cancers
Saif, Wasif M.
Cassier, Philippe Alexandre
Curigliano, Giuseppe
Daniele, Gennaro
Hilton, John Frederick
Koganemaru, Shigehiro
Kowalyszyn, Ruben
Lorusso, Patricia
Moreno, Victor
Olmedo Garcia, Maria Eugenia
Perroud, Herman Andres
Symeonides, Stefan N.
Yamamoto, Noboru
Aziez, Amine
Anjum, Rana
Lamacchia, John
Sembhi, Harjeet
Ratia, Nirav
Italiano, Antoine
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS847 - TPS847
[48] Preclinical development of a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer
Son, Thomas
Scribner, Juniper A.
Hooley, Jeff
Chiechi, Michael
Li, Pam
Hotaling, Timothy E.
De Costa, Anushka
Chen, Yan
Chen, Francine
Barat, Bhaswati
Ciccarone, Valentina
Gaynutdinov, Timur
Tamura, James
Koenig, Scott
Johnson, Syd
Moore, Paul A.
Bonvini, Ezio
Loo, Deryk
CANCER RESEARCH, 2017, 77
[49] ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3-targeting antibody-drug conjugate, in patients with advanced solid tumor
Wang, Jie
Duan, Jianchun
Xing, Ligang
Sun, Yuping
Guo, Wei
Wang, Haiying
Chen, Jianhua
Han, Liang
Liu, Baogang
Wang, Qiming
Hu, Ying
Wei, Hongying
Li, Chuan
Huang, Qiqi
Dong, Yiwei
Wu, Qiong
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[50] Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer
Altan, Mehmet
Kidwell, Kelley M.
Pelekanou, Vasiliki
Carvajal-Hausdorf, Daniel E.
Schalper, Kurt A.
Toki, Maria, I
Thomas, Dafydd G.
Sabel, Michael S.
Hayes, Daniel F.
Rimm, David L.
NPJ BREAST CANCER, 2018, 4

← 1 2 3 4 5 →